Clinical and virologic assesment of two therapeutic options: antiviral Ganciclovir 0.15% ophthalmic gel and physiologic saline solution 0.9% used in patients with acute adenoviral conjuntivitis.

Ana Boto de los Bueis0 个研究点开始时间: 2014年8月11日最近更新: 2015年7月10日

适应症

试验速览

暂无简介。

•1. Male or female aged ? 18 years old
•2. Patients with uni or bilateral folicular conjunctivitis (7 days) and at least one of the following signs:
•-Tarsal micro-haemorrhages
•-Preauricular lynphadenopathy
•-Previous or ongoing upper respiratory disease
•-Known history of recent contact with viral conjunctivitis
•-Iatrogenic exposure to viral infection (ophtlamologist, health-care center) during last 7 days
•3. Patients understanding complexity of the study and agree with signed informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 28
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 8

•1. Patients having viral conjunctivitis sympomathology longer tan 7 days.
•2 Patients showing fluorescein-stained cornea: geographic or dendritic distribution.
•3. Patients with corneal subepithelial infiltrates.
•4. Patients with severe dry eye.
•5. Intraocular inflammation (uveítis).
•6. Patients under systemic corticoid treatment because of systemic pathology having no relation with any exclusión criteria.
•7.Known history of atopy
•8. Known history of allergy to medicinal study treatment active ingredients or any other ingredient.
•The protocol also defines other exclusion criteria such as systemic/non ophthalmic exclusion criteria, specific exclusion criteria for women, exclusion criteria related to general and ethic conditions and exclusion criteria related to previous and concomitant medications/ non-product therapies.

发起方

Ana Boto de los Bueis